Business Context and Reporting Period
This Form 20-F is the annual report for Acasti Pharma Inc. (Note: The input metadata referenced "Grace Therapeutics," but the filing text explicitly identifies the registrant as Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc.). The report covers the fiscal year ended February 29, 2016. Acasti is a clinical-stage biopharmaceutical company focused on developing krill oil-based omega-3 phospholipid therapies, primarily its prescription drug candidate CaPre® for severe hypertriglyceridemia. The company also holds rights to ONEMIA®, a medical food product, though it has shifted focus to CaPre® development.
Key Financial Metrics
| Metric (CAD) | Fiscal 2016 | Fiscal 2015 |
|---|---|---|
| Revenue from Sales | $37,656 | $270,615 |
| Net Loss | $(6,316,731) | $(1,654,724) |
| Loss per Share (Basic & Diluted) | $(0.59) | $(0.16) |
| Research & Development Expenses | $7,389,415 | $8,856,941 |
| Total Assets | $28,517,322 | $37,208,105 |
| Cash and Short-Term Investments | $10,470,058 | $18,381,900 |
| Total Liabilities | $1,297,290 | $3,979,786 |
| Working Capital | $10,184,497 | $18,019,885 |
Note: All figures are in Canadian Dollars (CAD) unless otherwise specified. The company reported a gross loss of $43,762 for the year ended February 29, 2016, compared to a gross profit of $35,524 in the prior year.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped significantly by approximately 86% (from $270,615 to $37,656). This decrease is attributed to the strategic decision to find alternatives for ONEMIA® and focus resources on CaPre® development. Acasti entered a non-exclusive licensing agreement with its parent, Neptune, for ONEMIA® distribution, but no royalty revenue was recognized in 2016.
- Net Loss Increase: The net loss widened to $6.32 million from $1.65 million. While operating expenses decreased slightly, the net loss was exacerbated by a reduction in the gain from the change in fair value of derivative warrant liabilities (a gain of $2.2 million in 2016 vs. $8.8 million in 2015) and lower foreign exchange gains.
- Asset Impairment: The company recorded an impairment loss of $339,106 related to patents, determining the recoverable amount was nil due to uncertainties regarding project-level revenues.
- Liquidity Position: Cash and short-term investments decreased by approximately $7.9 million, primarily due to the maturity of investments held and operating cash outflows. However, the company maintains a positive working capital position.
Guidance, Outlook, and Risks
- CaPre® Development: The company is corresponding with the FDA regarding the next steps for CaPre®, including a pivotal Phase III clinical program. Acasti intends to pursue a 505(b)(2) regulatory pathway and has initiated a bioavailability bridging study. Commercialization is not expected until fiscal year 2021 at the earliest.
- Capital Requirements: Management expects to continue incurring substantial losses. While current cash and short-term investments ($10.47 million) are deemed sufficient for the next 12 months, the company will require additional capital to fund Phase III trials, NDA filing, and commercialization. Future financing may involve equity or debt offerings, strategic alliances, or collaborations.
- Key Risks:
- Regulatory Approval: No assurance exists that CaPre® will receive FDA approval. Failure to obtain approval would materially impair the business.
- Competition: The market for omega-3 therapies is competitive, with established players (e.g., GlaxoSmithKline, AstraZeneca) and generic versions of existing drugs.
- Supply Chain: Acasti relies on third parties for the supply of raw krill oil and manufacturing of CaPre® under cGMP standards.
- NASDAQ Compliance: The company received notice from NASDAQ regarding non-compliance with audit committee composition rules following director resignations. It has until March 1, 2017, or its next annual meeting to regain compliance to avoid delisting.
Investor Verification Checklist
- Cash Runway: Verify if the $10.47 million in cash and short-term investments is sufficient to fund the planned Phase III trials and NDA filing without immediate dilution.
- FDA Pathway: Confirm the status of the bioavailability bridging study results and the FDA's feedback on the 505(b)(2) regulatory strategy.
- NASDAQ Status: Monitor the company's progress in regaining compliance with NASDAQ audit committee requirements to prevent delisting.
- ONEMIA® Royalties: Track whether the licensing agreement with Neptune generates any royalty revenue in future periods.
- Related Party Transactions: Review the extent of reliance on Neptune for administrative services, R&D costs, and raw material supply.